Literature DB >> 23210632

Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma.

Guoqing Wei1,2, Uzoma Nwakuche1, Gustavo Cadavid1, Asim Ajaz1, Karen Seiter1, Delong Liu1.   

Abstract

Entities:  

Year:  2012        PMID： 23210632      PMCID： PMC3506991          DOI： 10.1186/2162-3619-1-3

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN： 2162-3619


× No keyword cloud information.
  3 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

Authors:  Mojtaba Akhtari; Edmund K Waller; David L Jaye; David H Lawson; Ramy Ibrahim; Nicholas E Papadopoulos; Martha L Arellano
Journal:  J Immunother       Date:  2009-04       Impact factor: 4.456

Review 3.  Current management and novel agents for malignant melanoma.

Authors:  Byung Lee; Nikhil Mukhi; Delong Liu
Journal:  J Hematol Oncol       Date:  2012-02-14       Impact factor: 17.388
  3 in total
  6 in total

1.  Serious haematological toxicity during and after ipilimumab treatment: a case series.

Authors:  Ester Simeone; Antonio Maria Grimaldi; Assunta Esposito; Marcello Curvietto; Marco Palla; Miriam Paone; Nicola Mozzillo; Paolo Antonio Ascierto
Journal:  J Med Case Rep       Date:  2014-07-01

2.  Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.

Authors:  Junling Zhuang; Jianhua Du; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-03       Impact factor: 3.500

3.  Ipilimumab-Induced Neutropenia in Melanoma.

Authors:  Makiko Ban-Hoefen; Richard Burack; Lynn Sievert; Deepak Sahasrabudhe
Journal:  J Investig Med High Impact Case Rep       Date:  2016-08-09

4.  Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.

Authors:  J Boegeholz; C S Brueggen; C Pauli; F Dimitriou; E Haralambieva; R Dummer; M G Manz; C C Widmer
Journal:  BMC Cancer       Date:  2020-04-14       Impact factor: 4.430

5.  Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Nabil E Omar; Kareem A El-Fass; Abdelrahman I Abushouk; Noha Elbaghdady; Abd Elmonem M Barakat; Ahmed E Noreldin; Dina Johar; Mohamed Yassin; Anas Hamad; Shereen Elazzazy; Said Dermime
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

6.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.